Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank You AntiMarv, That's good and the associated epitome spreading is good. I know they are using MAGE-A4, PRAME, NY-ESO-1, etc.
If you can reactivate the endogenous immune system, and also add additional antigen targets for each specific cancer, it has to be more beneficial, I just don't know if the improvement will be so much better as to justify starting a new trial.
I'll leave that up to MRKR, they will do the right thing.
Sounds like Greenpoint Brooklyn, half Italian and half Polish.
Thank You Phantom, I have been in a dilemma concerning this "not optimized for PC".
On one hand, you would hate to waste all of the time and money and progress already put into PC trial.
But on the other hand, why go forward and play the game without your best team on the field (antigens targeted and optimized for PC).
Would MRKR and Baylor proceed with current AND have a partner pay for all the costs of the "best team" against PC? And other cancers?
If Peter gave you a vote, what would you do?
It's helpful to get inside of your thinking process, at least to me.
"hey I’m Italian and my genetic makeup doesn’t afford me the luxury to tamper my emotions."
YEP, Dad came over from Sicily, Mom from Naples.
Been in those same "not good news" situations - PPHM killed me.
But, being that no one was talking about PC 2 months ago, I can't see any drop being that big, and also the therapy for PC is not really for PC, if I understand correctly, they didn't target antigens for PC, they are using the 5 AML antigens.
I believe Phantom or others can confirm this:
We're guessing that PC data will be good.
Is it correct that the therapy MRKR is using for PC is NOT targeting specific antigens for PC, they are using the AML therapy TAA's for PC?
GEEZ, if data is good, and you are not even targeting antigens for PC!!
From Oppenheimer:
"responses to MultiTAA therapy have been achieved without lymphodepletive preconditioning and cytokine support and at considerably lower doses vs. other adoptive T cell therapies. If results from the early BCM studies can be validated in a larger, multi-center trial, we believe MultiTAA could provide a distinct safety advantage over the current generation of CAR-T and TIL products."
YEP
"While our valuation rests on the potential of MultiTAA in AML, we acknowledge the broader potential of MultiTAA in other cancers. Later this month, we expect BCM to present first-in-human data from an ongoing trial in pancreatic cancer, MultiTAA’s first solid tumor indication. Given low investor expectations for cell therapies in this indication, we see little downside risk heading into the readout."
YEP
First line: "While our valuation rests on the potential of MultiTAA in AML, we acknowledge the broader potential of MultiTAA in other cancers."
is that an understatement or what?
In October 2018 (post #24854), in response to why MultiTAA was so undervalued compared to CAR-T, I said that because it was not genetically engineered, it was not "now" or "sexy", it just wasn't as fashionable as CAR-T or CRISPR.
I think on July 22nd, MultiTAA becomes now or fashionable.
I HOPE!
Can we close above $9 by Friday?
But why on earth would they do that?? Bet against a stock going to $50 AND pay 38% interest.
CRAZY
Couldn't help myself.
Bought another 5000 shares this morning.
Took two orders at the same price to fill.
Filled Buy 3510 MRKR Limit 8.2362 11:48:57 07/08/19
Filled Buy 1490 MRKR Limit 8.2362 11:48:57 07/08/19
$8.15 this week?
Eagle1 - NO, no options for me. At the time of the merger vote, I had 15,700 shares. Now just under 20,000 (most of the extra shares were free due to profits from short term trades since merger).
That's enough investment (122k) for me in one stock.
BTW, if we do get our giant pop up in price, even though it will continue to climb higher and higher for the next couple of years, either because of profit taking or new shorts or both, there will be decent pullbacks along the way that will just present new opportunities for short term trading.
Good Luck with your "$10's".
Or AXSM in 2019 - $3 - $27
Remember what SRPT did in 2017? $30 to $160.
Being that there was no IPO, other than the founders, a few large investors (NEA etc), and us TPIV investors, who has even heard of MRKR?
I'm hoping we get introduced to them very soon.
If TYME is a "success" achieving 6.4 months median overall survival versus 2.5 months for pancreatic patients, how great does that look for MRKR?
Tyme Technologies said before the open that data from the study of SM-88 as an oral monotherapy (for pancreatic cancer) revealed that the median overall survival of patients was 6.4 months, which compares favorably next to historical trials that showed survival of 2.0 to 2.5 months.
6.4 months?
Questions for Xena.
Forgetting about Parkinson's or Rett right now, for Alzheimer's, if I understand correctly, the trial study end date is November 2020.
Are there any anticipated data releases or any catalysts in the near (2019) future?
Is it correct that there are only 32 participants in this Alzheimer's study?
Do you believe that 32 participants will be enough for the FDA to make a positive judgement?
THANKS
WELL, I bought more shares on Wednesday. I did not know about the shelf registration, just wanted to add to my position as I was expecting some good news soon.
MRKR is in this exact same position. Supposed to announce good news on pancreatic cancer on July 20 and ALSO just did a shelf registration.
The thinking is they did that so it is available AFTER the good news.
AFTER the good news and AFTER the price pops way up, they take advantage of the price pop and THEN they raise capital for future trails.
Why couldn't this be the same case for AVXL.
For either company, I don't know one way or the other, but I do know this, after reading all of todays comments here. I'd rather see $5 than $2.
I guess me and you all will be finding out pretty soon huh?
If you accumulate at $5 or at $8, it is not going to matter to you when it is $50 or $80.
$17 is good but I hope you're wrong. I've seen too many biotechs go up 350%, 450%, 650%, etc, in one day on good trial news.
Would love mid $20's to $40.
Happy 4th of July everybody. Go MRKR - Go America
MRKR $8 to $40 - July 20 data. AVXL $4 will test $6 soon.
AVXL also up, up and away.
CLAY is CORRECT on MRKR. $8 now, going to be closer to $40 after the July 20 pancreatic cancer data.
Next Under Radar Lotto pick is MRKR.
Pancreatic cancer data/cure announcement coming July 20th.
<$8 now, $30 to $40 3 weeks from now.
SERIOUSLY - do just a little DD and profit.
Come On ATNM, go down to .2222.
One month from now - I can hear the voices:
OH, why didn't I buy more when it was $7.50.
Oh, why didn't I but more when it was $8.50.
I should've bought more under $10.
… not too late …
I think all the recent enthusiasm in pancreatic results are because it's solid, as opposed to blood. Just SO much more potential, especially with their ability to add antigens targets.
Many things are very binary, like supply and demand, or risk versus reward.
As you say, the potential risk in MRKR is VERY LOW and the potential reward is VERY, VERY, VERY HIGH.
Seems like a NO BRAINER to me right now.
As much as QCOM, NVDA, and ALNY were no brainers at the time.
If JUNO was 9 bil and KITE was 12 bil … 15 to 20 billion.
Definitely expecting POP. I see you also on AVXL board, looks like a pop ready there also. I got out of CYTR a long time ago.
The only thing I can say for sure is, there is an order in to buy a large amount if the price goes down to .2222
nice move today, Buy Now before the real move up.
YEA, closed above $8, About Time.
You know, even if we get good PC news,
that's just the beginning of the story.
If we continue with NO cytokine release syndrome,
if we continue to get beneficial epitome spreading,
if we can add antigen targets for different cancers,
if we show trial success with solid tumors,
This story will be a best selling novel.
We are just finishing to read the prologue.
Chapter one starts July 20th.
Hopefully it starts similar to "A Tale of One City"
"It was the best of times, it was the age of wisdom, it was the epoch of belief, it was the spring of hope".
You know what it is, at least in my head.
Everybody "does stocks" their own way.
But no matter "what way" someone does stocks, you have to admit, there are just so many Weird signals that one doesn't ordinarily get.
The news conference 2 days after data, not if it was bad data.
The way Peter smiled in the Sachs video when he talked about the PC data being presented.
Peter saying shorts held to the 3rd quarter would get burned.
I'm not a chart guy so I don't look for signposts, but there sure seems to be a lot of signposts.
If these price guesstimates are correct, people with 20, 50, 80 thousand invested, they're looking at some Serious money coming in.
Over 100K, it's kind of nerve wracking right now for many, I imagine.
I love your answer, boy do I hope so.
If you would, can you please keep us informed on what the options activity is doing until July 20?
Thank You